Abstract:Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. The impairment of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH), adrenal hyperplasia, and excessive androgen synthesis. The syndrome is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency. The clinical manifestations of CAH in adults result from adrenocortical and adrenomedullary insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids used for the treatment of the condition. Non-classic CAH may sometimes be asymptomatic. In patients with classic CAH obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia are more often seen than in the general population. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction, and cardiovascular disease. Long-term glucocorticosteroid treatment is also a known risk factor for osteoporosis. Patients with CAH require constant monitoring of biochemical parameters (17a-hydroxyprogesterone [17-OHP] and androstenedione), clinical parameters (body mass, waist circumference, blood pressure, glucose, and lipids), and bone mineral density by densitometry. The principal goal of treatment in adults with CAH is to improve quality of life, ensure that they remain fertile, reduce the manifestations of hyperandrogenisation in females, and minimise the adverse effects of glucocorticosteroid treatment. Patients with classic CAH require treatment with glucocorticosteroids and, in cases of salt wasting, also with a mineralocorticosteroid. Radical measures, such as bilateral adrenalectomy, are very rarely needed. Asymptomatic patients with non-classic CAH require monitoring: treatment is not always necessary. Medical care for patients with CAH should be provided by reference centres, as the management of such patients requires collaboration between an endocrinologist, diabetologist, gynaecologist, andrologist, urologist, and psychologist.

Development in diagnosis and treatment of congenital adrenocortical hyperplasia

Treatment for Congenital Adrenal Hyperplasia with 21-Hydroxylase Deficiency

A3309 Clinical and Genetic Analysis of a Pedigree with Congenital Adrenal Hyperplasia (17Α-Hydroxylase /17,20-Lyase Deficiency) Literature

Congenital adrenal hyperplasia disorder due to 17 α-hydroxylase deficiency: a case report

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults

Retrospective Analysis of Early Treatment of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

Clinical features of 9 patients with X-linked adrenal hypoplasia congenita caused by DAX1/NR0B1 gene mutations

A Novel Compound Heterozygous CYP17A1 Variant Causes 17α-Hydroxylase/17, 20-Lyase Deficiency.

Molecular Physiopathology, Late Diagnoses, and Personalized Management

Cardiometabolic Aspects of Congenital Adrenal Hyperplasia

Current status and prospects of congenital adrenal hyperplasia: A bibliometric and visualization study

Recent progress of 11β-hydroxylase deficiency

Clinical and Gene Analysis among One Family Members of Congenital Adrenal Hyperplasia

Evaluating the efficacy of a long-read sequencing-based approach in the clinical diagnosis of neonatal congenital adrenocortical hyperplasia

Prenatal diagnosis and in utero treatment of congenital adrenal hyperplasia: An up‐to‐date comprehensive review

Genetic diagnosis and clinical analysis of 17α-hydroxylase/17, 20-lyase deficiency combined with type 2 diabetes mellitus: A case report

[Consensus on Laboratory Diagnosis of Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency].

Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia

Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management

Adrenal myelolipoma with congenital 17a-hydroxylase deficiency: a pedigree report and review of the literature

Establishment of an Assay for Detection of Gene Mutation in Congenital Adrenal Hyperplasia